Veradermics Pill Shows Gains in Male Hair Loss

Phase 2/3 Study 302 reports improved hair growth and coverage for an oral minoxidil formulation over 12 months in men with pattern hair loss.

Updated on Nov. 9, 2026 in Men’s Health

Vector editorial illustration of a single teal capsule beside a cluster of coral hair strands on a cream background, evoking an oral treatment for hair regrowth.
Veradermics reported that its oral minoxidil pill VDPHL01 produced hair growth gains over 12 months in a Phase 2/3 study of 519 men with pattern hair loss. AI Illustration. Upload story photo >

Live Poll

Would you take a daily oral pill for thinning hair if it were FDA-approved?

Veradermics announced positive topline results from Part B of Study 302, evaluating its investigational oral minoxidil formulation VDPHL01 in 519 men with mild-to-moderate pattern hair loss. The twice-daily 8.5mg cohort gained 43.9 non-vellus hairs per square centimeter from baseline to Month 12.

Why it matters

Pattern hair loss affects a large population of American men, and a daily oral option would offer an alternative to topical treatments. The company says the findings could position the therapy as the first FDA-approved oral pill for pattern hair loss in nearly 30 years.

Study 302 enrolled 519 men, and the twice-daily 8.5mg cohort showed 89.1% of participants noting visible coverage improvement versus 79.8% in the once-daily cohort. Results are from a six-month placebo-controlled period extended to Month 12, and female trial data remain pending.

The players

Veradermics

Veradermics is the clinical-stage company developing VDPHL01, an investigational oral minoxidil formulation for hair loss.

The details

Study 302 tested once-daily and twice-daily 8.5mg doses of VDPHL01 against a placebo for six months, after which placebo participants crossed over to active treatment and all were evaluated at Month 12. The company reported no treatment-related serious adverse events across 12 months and no treatment-emergent discontinuations between Month 6 and Month 12.

Timeline

  1. Month 6: Placebo participants crossed over to active treatment in Study 302.

  2. Month 12: Final efficacy measurements were taken for Study 302 participants.

  3. November 9, 2026: Veradermics announced Part B topline results.

  4. First half of 2027: Veradermics expects female pattern hair loss trial data.

Health Landscape

Topical minoxidil has long been the standard over-the-counter option for pattern hair loss, and Study 302 tests whether a registration-directed oral formulation can match it. If approved, VDPHL01 would be the first oral pill for pattern hair loss to reach the market in nearly 30 years.

If approved, an oral pill could offer men with pattern hair loss an alternative to applying topical treatments each day. Readers considering hair loss treatment should discuss options, including oral minoxidil, with a clinician, since VDPHL01 is not yet approved.

The takeaway

Early trial data suggest oral minoxidil may improve hair growth and coverage in men with pattern hair loss over a year of treatment. Results remain investigational, so patients should wait for regulatory decisions and female trial data before expecting access.

What happens next

Veradermics expects female pattern hair loss trial data in the first half of 2027.

Further reading

For related coverage, explore more Men’s Health reporting on treatments and conditions affecting men.

Source note: This article includes information reported by Benzinga.

Live Poll

Would you take a daily oral pill for thinning hair if it were FDA-approved?